Author:
Figueroa Salvador Cabrera,Gómez Alicia Iglesias,Martín Almudena Sánchez,de la Paz Valverde Merino María,Hurlé Alfonso Domínguez-Gil,Sánchez Miguel Cordero
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference37 articles.
1. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008 Jan 29: 1-128 [online]. Available from URL: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 2009 Jul 26]
2. Blanch J, Martinez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001 Aug 1; 27(4): 336–43
3. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 2002 Jul; 22(7): 930–3
4. U.S. Food and Drug Administration. Sustiva label information, approved 2008 Aug 18 [online]. Available from URL: http://www.fda.gov/cder/foi/label/2008/020972s030,021360s019lbl.pdf [Accessed 2009 Jul 15]
5. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999 Dec 16; 341(25): 1865–73
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献